DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Clinical Development of Gamitrinib, a Novel Mitochondrial-Targeted Small Molecule Hsp90 Inhibitor
Annual rept. 1 Sep 2013-31 Aug 2014
WISTAR INST OF ANATOMY AND BIOLOGY PHILADELPHIA PA
Pagination or Media Count:
Considerable progress has been made during the past budget cycle on all of the specific tasks set forth in the SOW for the present proposal. The overarching goal of Specific Aim 1 months 0-12 of award has been accomplished, with the identification of a novel metabolomics protein signature of Gamitrinib anticancer activity, in vivo i, the characterization of protein biomarkers of Gamitrinib function in genetic models of prostate cancer ii, and the further biochemical characterization of the target of Gamitrinib, TRAP-,1 in tumor bioenergetics and metabolic reprogramming iii. Altogether, the work supported by the present award led to the publication of two articles directly relevant to the scopes of the present SOW Chae et al Nat Comm. 42139 Lisanti et al Cell Rep 6177, the submission for publication of a third original article Ghosh et al submitted, and the presentation of some of the SOW research findings at a national conference Keystone Conference on Mitochondrial Dynamics and Physiology, Santa Fe, NM -1822014 2322014.
APPROVED FOR PUBLIC RELEASE